AXSM News and Press, Axsome Therapeutics Inc. From 02/20/24

2024-02-20 07:10:40 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics Q4 2023 Earnings Preview UBS starts Axsome at buy, sees Au...

Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, respectively, during the first full year of launch...

Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...

2024-02-16 13:24:18 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030 Axsome Thera...

2024-02-08 18:05:29 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics a new outperform at RBC on underappreciated pipeline New A...

2024-02-08 07:45:00 ET In the investing world, a two-bagger refers to a stock that gains 100% -- that is, it doubles your initial capital. Doing so in a mere five years is no easy feat. It requires a compound annual growth rate (CAGR) of about 14.9% -- which, incidentally, is pretty much wh...

2024-02-07 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

2024-01-26 13:17:16 ET More on Vera Therapeutics Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect Vera hits 52-week high after long-term data for lead asset (update) Vera gains as Jefferies upgrades to Buy on lead asset Seeking Al...

2024-01-25 23:11:51 ET Summary Lundbeck's new CEO has laid out a plan to maximize the value of the company's current portfolio, reorganize R&D, and deploy capital towards growth-sustaining M&A. The company aims to maximize the value of its current portfolio, particularly f...